A first-in-human Phase 1 trial of NIR-PIT with the APC targeting epidermal growth factor receptor (EGFR) in patients with inoperable head and neck cancer was approved by the US FDA, and is underway (https://clinicaltrials.gov/ct2/show/NCT02422979). This evidence concerns the gene EGFR and head and neck cancer.